In its 10th year, the Lancet Countdown’s findings are stark: real progress in clean energy, adaptation, and evidence is being outpaced by faster-growing harm.

Sickle cell disease is the most common haemoglobinopathy, affecting more than 7 million people worldwide.1 Despite ...

The treatment landscape of EGFR-mutated non-small-cell lung cancer harbouring exon 19 deletion or L858R mutations has advanced remarkably over the past two decades. Although acquired resistance to ...

For 70 years, corticosteroids have been the default treatment for sarcoidosis.1 Although the field has repeatedly tried to find alternatives, studies have struggled with the heterogeneity of disease, ...

Latvia has one of the world's highest rates of alcohol consumption but recent policy changes are starting to lessen direct harms to health. Ed Holt reports.

Africa’s digital health revolution, marked by a rapid increase in the number of technologies and providers of electronic ...

Cancer experts fear a rise in cancer cases in Russia if a draft 2027 budget proposing a sharp cut of more than 90% in federal ...

It was a 2015 Editorial in The Lancet Oncology discussing cancer in the transgender community, that set Alison Berner (Queen ...

We thank Jordan Bakhriansyah and colleagues for their thoughtful commentary on our manuscript from the ATLAS individual patient data meta-analysis.1 Although their conceptual arguments merit ...

About two decades after the initial description of anti-NMDA receptor encephalitis, autoimmune encephalitis has expanded from ...

The proportion of the world's oncology trials delivered within Europe has fallen from 41% in 2008 to 21% in 2023, according ...

Although climate change represents one of the greatest public health challenges of our time, its impacts on patients with ...